Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications
Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.
Journal: Hematology (Amsterdam, Netherlands)
Published: September 01, 2026
Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.
Journal: Future oncology (London, England)
Published: August 30, 2026
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.
Journal: Nature medicine
Published: July 06, 2026
Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Journal: The New England journal of medicine
Published: June 15, 2026
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.
Journal: The New England journal of medicine
Published: December 08, 2025
Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis.
Journal: Annals of hematology
Published: August 27, 2025
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma.
Journal: Cancer medicine
Published: January 22, 2025
Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results.
Journal: Clinical pharmacology and therapeutics
Published: October 02, 2024
Last Updated: 09/26/2026